CTMX
Price
$4.06
Change
+$0.16 (+4.10%)
Updated
Dec 11 closing price
Capitalization
687.91M
82 days until earnings call
Intraday BUY SELL Signals
REGN
Price
$746.80
Change
+$20.59 (+2.84%)
Updated
Dec 11 closing price
Capitalization
78.49B
49 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CTMX vs REGN

Header iconCTMX vs REGN Comparison
Open Charts CTMX vs REGNBanner chart's image
CytomX Therapeutics
Price$4.06
Change+$0.16 (+4.10%)
Volume$1.39M
Capitalization687.91M
Regeneron Pharmaceuticals
Price$746.80
Change+$20.59 (+2.84%)
Volume$1.15M
Capitalization78.49B
CTMX vs REGN Comparison Chart in %
CTMX
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CTMX vs. REGN commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTMX is a StrongBuy and REGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (CTMX: $4.06 vs. REGN: $746.80)
Brand notoriety: CTMX: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CTMX: 47% vs. REGN: 107%
Market capitalization -- CTMX: $687.91M vs. REGN: $78.49B
CTMX [@Biotechnology] is valued at $687.91M. REGN’s [@Biotechnology] market capitalization is $78.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CTMX’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • CTMX’s FA Score: 2 green, 3 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, CTMX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CTMX’s TA Score shows that 2 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • CTMX’s TA Score: 2 bullish, 5 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, REGN is a better buy in the short-term than CTMX.

Price Growth

CTMX (@Biotechnology) experienced а -0.49% price change this week, while REGN (@Biotechnology) price change was +3.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

CTMX is expected to report earnings on Mar 04, 2026.

REGN is expected to report earnings on Jan 30, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($78.5B) has a higher market cap than CTMX($688M). REGN has higher P/E ratio than CTMX: REGN (17.90) vs CTMX (13.53). CTMX YTD gains are higher at: 294.175 vs. REGN (2.386). REGN has higher annual earnings (EBITDA): 5.42B vs. CTMX (44.7M). REGN has more cash in the bank: 7.47B vs. CTMX (158M). CTMX has less debt than REGN: CTMX (6.89M) vs REGN (2.71B). REGN has higher revenues than CTMX: REGN (14.2B) vs CTMX (141M).
CTMXREGNCTMX / REGN
Capitalization688M78.5B1%
EBITDA44.7M5.42B1%
Gain YTD294.1752.38612,332%
P/E Ratio13.5317.9076%
Revenue141M14.2B1%
Total Cash158M7.47B2%
Total Debt6.89M2.71B0%
FUNDAMENTALS RATINGS
CTMX vs REGN: Fundamental Ratings
CTMX
REGN
OUTLOOK RATING
1..100
1072
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
1354
PRICE GROWTH RATING
1..100
3644
P/E GROWTH RATING
1..100
1057
SEASONALITY SCORE
1..100
5043

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for CTMX (65). This means that REGN’s stock grew somewhat faster than CTMX’s over the last 12 months.

REGN's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as CTMX (100). This means that REGN’s stock grew similarly to CTMX’s over the last 12 months.

CTMX's SMR Rating (13) in the Biotechnology industry is somewhat better than the same rating for REGN (54). This means that CTMX’s stock grew somewhat faster than REGN’s over the last 12 months.

CTMX's Price Growth Rating (36) in the Biotechnology industry is in the same range as REGN (44). This means that CTMX’s stock grew similarly to REGN’s over the last 12 months.

CTMX's P/E Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for REGN (57). This means that CTMX’s stock grew somewhat faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CTMXREGN
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
37%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 3 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 3 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 3 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 3 days ago
66%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 18 days ago
64%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 4 days ago
51%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
45%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
CTMX
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOVAX26.740.26
+0.98%
First Trust/Confluence Small Cap Val A
TICHX30.930.23
+0.75%
Nuveen Large Cap Responsible Eq I
MKCPX28.610.06
+0.21%
BlackRock Balanced K
SWLSX43.65-0.05
-0.11%
Schwab Large-Cap Growth
GSIOX31.77-0.99
-3.02%
Goldman Sachs Small Cap Gr Insghts Instl

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with BMRN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+4.86%
BMRN - REGN
44%
Loosely correlated
-0.07%
SMMT - REGN
39%
Loosely correlated
+5.41%
ARQT - REGN
37%
Loosely correlated
+0.03%
ROIV - REGN
37%
Loosely correlated
-0.93%
IDYA - REGN
36%
Loosely correlated
-1.29%
More